Grant Number:	5U01CA195568-09 Interpret this number
Primary Investigator:	Cerhan, James
Organization:	Mayo Clinic Rochester
Project Title:	The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
Fiscal Year:	2024

PROJECT SUMMARY In 2020, an estimated 77,240 people in the US will be diagnosed with non-Hodgkin lymphoma (NHL), and 19,940 will die from this cancer. NHL incidence rates increased over the last half of the 20th century and only recently stabilized. In parallel, NHL survival rates began improving in the mid-1990s with the advent of improved treatment strategies, leading to the current 5-year survival rate of 74%. These trends have led to a growth in the number of NHL survivors, estimated at over 757,000 in 2019. To address the unmet health needs of this patient population, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study, which by June 2020 will have enrolled over 13,000 NHL patients and have <1% lost to follow-up. The LEO cohort supports multiple grants and has generated novel and high impact findings on NHL prognosis and survivorship. To continue and expand the key contributions of LEO, in this renewal we propose to: 1) Extend recruitment at all 8 LEO centers, with a goal of recruiting 3400 newly diagnosed NHL patients focused on Hispanic (N=900), African American (N=580), and Asian (N=200) participants (doubling the current sample size for these groups) and adolescent and young adult (AYA) participants age 18-39 years (N=870; 87% increase), and non-metro and rural patients of all ages and race/ethnicities (N=1,208, 72% increase), for a total cohort of 16,500 patients; 2) Review all pathology diagnoses and maintain a NHL tumor bank that includes an H&E slide, formalin-fixed, paraffin-embedded tissue samples in a tissue microarray, and extracted tumor DNA and RNA; 3) Collect a peripheral blood sample and maintain a central biorepository of DNA, serum, plasma and buffy coat; 4) Annotate and harmonize all cases with clinical, epidemiologic, pathology and treatment data, including development of new informatics enhancements to capture clinical data from electronic health records, digital pathology images and linkage to public databases to enhance data on environmental exposures and socioeconomic factors; 5) Prospectively follow patients in the cohort to ascertain disease progression/relapse, retreatment, transformation, second cancers, survival (including cause of death), updated exposures, patient- reported outcomes (PROs), and other long-term health outcomes; and 6) Facilitate research projects that use this infrastructure, promote interactions with NCI-supported clinical trials networks, patient advocacy groups, and other collaborators. We will achieve these aims through close coordination of each of the participating centers, supported by four cores (Administration; Clinical; Pathology & Biospecimens; and Biostatistics & Informatics). The LEO cohort is an exceptional resource that supports a broad research agenda aimed at identifying novel clinical, epidemiologic, germline genetic, tumor, and treatment factors that influence NHL prognosis and survivorship focusing on NCI research priorities in AYA, minority, and rural populations. LEO is led by international experts in clinical and epidemiologic research on NHL, thereby driving the translation of new findings to the clinic and the population.




Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature.
Authors: Bommier C. , Link B.K. , Gysbers B.J. , Maurer M.J. , Larson M.C. , Khurana A. , Wang Y. , Thompson C.A. , Chihara D. , Alderuccio J.P. , et al. .
Source: Blood Advances, 2024-12-10 00:00:00.0; 8(23), p. 5939-5948.
PMID: 39321424
Related Citations

Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial.
Authors: Friedberg J.W. , Brady M.T. , Strawderman M. , Kahl B.S. , Lossos I.S. , Cohen J.B. , Reagan P.M. , Casulo C. , Averill B.L. , Baran A. , et al. .
Source: Eclinicalmedicine, 2024 Dec; 78, p. 102959.
EPub date: 2024-11-27 00:00:00.0.
PMID: 39677358
Related Citations

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis.
Authors: Abro B. , Maurer M.J. , Habermann T.M. , Burack W.R. , Chapman J.R. , Cohen J.B. , Friedberg J.W. , Inghirami G. , Kahl B.S. , Larson M.C. , et al. .
Source: Blood, 2024-11-07 00:00:00.0; 144(19), p. 2063-2066.
PMID: 39255410
Related Citations

DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas.
Authors: Hopper M.A. , Dropik A.R. , Walker J.S. , Novak J.P. , Laverty M.S. , Manske M.K. , Wu X. , Wenzl K. , Krull J.E. , Sarangi V. , et al. .
Source: Blood Cancer Journal, 2024-10-09 00:00:00.0; 14(1), p. 172.
EPub date: 2024-10-09 00:00:00.0.
PMID: 39384745
Related Citations

Transformation of marginal zone lymphoma to Hodgkin lymphoma.
Authors: Moalem K.N. , Alderuccio J.P. , Bommier C. , Habermann T. , Link B.K. , Cerhan J.R. , Florindez J. , Lossos I.S. .
Source: Blood Advances, 2024-09-10 00:00:00.0; 8(17), p. 4559-4562.
PMID: 39024508
Related Citations

Risk of transformation by frontline management in follicular and marginal zone lymphomas: a US population-based analysis.
Authors: Florindez J.A. , Chihara D. , Reis I.M. , Lossos I.S. , Alderuccio J.P. .
Source: Blood Advances, 2024-08-27 00:00:00.0; 8(16), p. 4423-4432.
PMID: 38954843
Related Citations

Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL.
Authors: Khurana A. , Mwangi R. , Nastoupil L.J. , Reagan P.M. , Farooq U. , Romancik J.T. , McDonnell T.J. , Riska S.M. , Lossos L.S. , Kahl B.S. , et al. .
Source: Blood Advances, 2024-08-27 00:00:00.0; 8(16), p. 4414-4422.
PMID: 38991126
Related Citations

Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation.
Authors: Stokes M.E. , Wenzl K. , Huang C.C. , Ortiz M. , Hsu C.C. , Maurer M.J. , Stong N. , Nakayama Y. , Wu L. , Chiu H. , et al. .
Source: Nature Communications, 2024-08-08 00:00:00.0; 15(1), p. 6790.
EPub date: 2024-08-08 00:00:00.0.
PMID: 39117654
Related Citations

Defining primary refractory large B-cell lymphoma.
Authors: Bock A.M. , Mwangi R. , Wang Y. , Khurana A. , Maurer M.J. , Ayers A. , Kahl B.S. , Martin P. , Cohen J.B. , Casulo C. , et al. .
Source: Blood Advances, 2024-07-09 00:00:00.0; 8(13), p. 3402-3415.
PMID: 38669353
Related Citations

Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL.
Authors: Wenzl K. , Stokes M.E. , Novak J.P. , Bock A.M. , Khan S. , Hopper M.A. , Krull J.E. , Dropik A.R. , Walker J.S. , Sarangi V. , et al. .
Source: Blood Cancer Journal, 2024-06-20 00:00:00.0; 14(1), p. 100.
EPub date: 2024-06-20 00:00:00.0.
PMID: 38902256
Related Citations

Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment.
Authors: Arcaini L. , Bommier C. , Alderuccio J.P. , Merli M. , Fabbri N. , Nizzoli M.E. , Maurer M.J. , Tarantino V. , Ferrero S. , Rattotti S. , et al. .
Source: Eclinicalmedicine, 2024 Jun; 72, p. 102592.
EPub date: 2024-04-11 00:00:00.0.
PMID: 38633575
Related Citations

Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP.
Authors: Bantilan K.S. , Smith A.N. , Maurer M.J. , Teruya-Feldstein J. , Matasar M.J. , Moskowitz A.J. , Straus D.J. , Noy A. , Palomba M.L. , Horwitz S.M. , et al. .
Source: Blood Advances, 2024-05-14 00:00:00.0; 8(9), p. 2172-2181.
PMID: 38271621
Related Citations

Translating prognostic quantification of c-MYC and BCL2 from tissue microarrays to whole slide images in diffuse large B-cell lymphoma using deep learning.
Authors: Tavolara T.E. , Niazi M.K.K. , Feldman A.L. , Jaye D.L. , Flowers C. , Cooper L.A.D. , Gurcan M.N. .
Source: Diagnostic Pathology, 2024-01-19 00:00:00.0; 19(1), p. 17.
EPub date: 2024-01-19 00:00:00.0.
PMID: 38243330
Related Citations

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
Authors: Cerhan J.R. , Maurer M.J. , Link B.K. , Feldman A.L. , Habermann T.M. , Jaye D.L. , Burack W.R. , McDonnell T.J. , Vega F. , Chapman J.R. , et al. .
Source: American Journal Of Hematology, 2024-01-13 00:00:00.0; , .
EPub date: 2024-01-13 00:00:00.0.
PMID: 38217361
Related Citations

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
Authors: Cerhan J.R. , Maurer M.J. , Link B.K. , Feldman A.L. , Habermann T.M. , Jaye D.L. , Burack W.R. , McDonnell T.J. , Vega F. , Chapman J.R. , et al. .
Source: American Journal Of Hematology, 2024-01-13 00:00:00.0; , .
EPub date: 2024-01-13 00:00:00.0.
PMID: 38217361
Related Citations

PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.
Authors: Alderuccio J.P. , Reis I.M. , Hamadani M. , Nachiappan M. , Leslom S. , Kahl B.S. , Ai W.Z. , Radford J. , Solh M. , Ardeshna K.M. , et al. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2024-01-05 00:00:00.0; 30(1), p. 139-149.
PMID: 37855688
Related Citations

Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
Authors: Maurer M.J. , Casulo C. , Larson M.C. , Habermann T.M. , Lossos I.S. , Wang Y. , Nastoupil L.J. , Strouse C. , Chihara D. , Martin P. , et al. .
Source: Haematologica, 2023-11-30 00:00:00.0; , .
EPub date: 2023-11-30 00:00:00.0.
PMID: 38031804
Related Citations

Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study.
Authors: Bock A.M. , Gile J.J. , Larson M.C. , Poonsombudlert K. , Tawfiq R.K. , Maliske S. , Maurer M.J. , Kabat B.F. , Paludo J. , Inwards D.J. , et al. .
Source: Blood Cancer Journal, 2023-11-13 00:00:00.0; 13(1), p. 169.
EPub date: 2023-11-13 00:00:00.0.
PMID: 37957158
Related Citations

Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.
Authors: Mastini C. , Campisi M. , Patrucco E. , Mura G. , Ferreira A. , Costa C. , Ambrogio C. , Germena G. , Martinengo C. , Peola S. , et al. .
Source: Science Translational Medicine, 2023-06-28 00:00:00.0; 15(702), p. eabo3826.
EPub date: 2023-06-28 00:00:00.0.
PMID: 37379367
Related Citations

Molecular classification and identification of an aggressive signature in low-grade B-cell lymphomas.
Authors: Hopper M.A. , Wenzl K. , Hartert K.T. , Krull J.E. , Dropik A.R. , Novak J.P. , Manske M.K. , Serres M.R. , Sarangi V. , Larson M.C. , et al. .
Source: Hematological Oncology, 2023-05-30 00:00:00.0; , .
EPub date: 2023-05-30 00:00:00.0.
PMID: 37254453
Related Citations

Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era.
Authors: Correia C. , Maurer M.J. , McDonough S.J. , Schneider P.A. , Ross P.E. , Novak A.J. , Feldman A.L. , Cerhan J.R. , Slager S.L. , Witzig T.E. , et al. .
Source: Blood Cancer Journal, 2023-05-17 00:00:00.0; 13(1), p. 81.
EPub date: 2023-05-17 00:00:00.0.
PMID: 37193683
Related Citations

Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma.
Authors: Alderuccio J.P. , Reis I.M. , Koff J.L. , Larson M.C. , Chihara D. , Zhao W. , Haddadi S. , Habermann T.M. , Martin P. , Chapman J.R. , et al. .
Source: Blood, 2023-04-13 00:00:00.0; 141(15), p. 1888-1893.
PMID: 36735908
Related Citations

Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas.
Authors: Alhaj Moustafa M. , Borah B.J. , Moriarty J.P. , Dholakia R. , Jiang L. , Li K. , Witzig T.E. , Hoppe B.S. , Peterson J. , Cerhan J.R. , et al. .
Source: Clinical Lymphoma, Myeloma & Leukemia, 2023 Apr; 23(4), p. 259-265.
EPub date: 2023-01-26 00:00:00.0.
PMID: 36775698
Related Citations

Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis.
Authors: Desai S.H. , Mwangi R. , Ng W.L. , King R.L. , Maurer M.J. , Cerhan J.R. , Feldman A.L. , Farooq U. , Mou E. , Habermann T.M. , et al. .
Source: Blood Advances, 2022-12-27 00:00:00.0; 6(24), p. 6180-6186.
PMID: 36170803
Related Citations

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.
Authors: Epperla N. , Switchenko J.M. , Bachanova V. , Gerson J.N. , Barta S.K. , Gordon M.J. , Danilov A.V. , Grover N.S. , Mathews S.P. , Burkart M. , et al. .
Source: Blood Advances, 2022-12-14 00:00:00.0; , .
EPub date: 2022-12-14 00:00:00.0.
PMID: 36516079
Related Citations

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma.
Authors: Desai S.H. , Mwangi R. , Smith A.N. , Maurer M.J. , Farooq U. , King R.L. , Cerhan J.R. , Feldman A.L. , Habermann T.M. , Thompson C.A. , et al. .
Source: Hematological Oncology, 2022-10-28 00:00:00.0; , .
EPub date: 2022-10-28 00:00:00.0.
PMID: 36305717
Related Citations

Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma.
Authors: Alderuccio J.P. , Reis I.M. , Habermann T.M. , Link B.K. , Thieblemont C. , Conconi A. , Larson M.C. , Cascione L. , Zhao W. , Cerhan J.R. , et al. .
Source: American Journal Of Hematology, 2022-09-03 00:00:00.0; , .
EPub date: 2022-09-03 00:00:00.0.
PMID: 36057138
Related Citations

A roadmap for clinical trial design in marginal zone lymphoma.
Authors: Alderuccio J.P. , Habermann T. , Kuker R. , Moskowitz C.H. , Zelenetz A.D. , Lossos I.S. .
Source: American Journal Of Hematology, 2022-08-28 00:00:00.0; , .
EPub date: 2022-08-28 00:00:00.0.
PMID: 36030403
Related Citations

Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis.
Authors: Luan D. , Fatola T. , Toure A. , Flowers C.R. , Link B. , Friedberg J.W. , Cohen J.B. , Kahl B. , Lossos I.S. , Nastoupil L. , et al. .
Source: Blood Advances, 2022-08-09 00:00:00.0; 6(15), p. 4413-4423.
PMID: 35793440
Related Citations

Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care.
Authors: Sidana S. , Allmer C. , Larson M.C. , Dueck A. , Yost K. , Warsame R. , Thanarajasingam G. , Cerhan J.R. , Paludo J. , Rajkumar S.V. , et al. .
Source: Jco Oncology Practice, 2022 Aug; 18(8), p. e1320-e1333.
EPub date: 2022-05-17 00:00:00.0.
PMID: 35580285
Related Citations

Causes of Death in Low Grade B-Cell Lymphomas in the Rituximab Era: A Prospective Cohort Study.
Authors: Tun A. , Khurana A. , Mwangi R. , Link B.K. , Wang Y. , Feldman A. , Thompson C.A. , Novak A.J. , Villasboas J.C. , Thanarajasingam G. , et al. .
Source: Blood Advances, 2022-07-18 00:00:00.0; , .
EPub date: 2022-07-18 00:00:00.0.
PMID: 35849723
Related Citations

Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis.
Authors: Strouse C.S. , Larson M.C. , Ehlers S.L. , Yost K.J. , Maurer M.J. , Ansell S.M. , Inwards D.J. , Johnston P.B. , Micallef I.N. , Link B.K. , et al. .
Source: Jco Oncology Practice, 2022 Jul; 18(7), p. e1069-e1080.
EPub date: 2022-05-20 00:00:00.0.
PMID: 35594505
Related Citations

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts.
Authors: Desai S.H. , Pederson L. , LaPlant B. , Mwangi R. , Maurer M. , Young J.R. , Macon W.R. , King R.L. , Wang Y. , Cerhan J.R. , et al. .
Source: Blood Cancer Journal, 2022-05-03 00:00:00.0; 12(5), p. 78.
EPub date: 2022-05-03 00:00:00.0.
PMID: 35504884
Related Citations

Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
Authors: Casulo C. , Larson M.C. , Lunde J.J. , Habermann T.M. , Lossos I.S. , Wang Y. , Nastoupil L.J. , Strouse C. , Chihara D. , Martin P. , et al. .
Source: The Lancet. Haematology, 2022 Apr; 9(4), p. e289-e300.
PMID: 35358443
Related Citations

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.
Authors: Castellino A. , Wang Y. , Larson M.C. , Maurer M.J. , Link B.K. , Farooq U. , Feldman A.L. , Syrbu S.I. , Habermann T.M. , Paludo J. , et al. .
Source: Blood Advances, 2022-02-22 00:00:00.0; 6(4), p. 1350-1360.
PMID: 34662895
Related Citations

Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria.
Authors: King R.L. , Khurana A. , Mwangi R. , Fama A. , Ristow K.M. , Maurer M.J. , Macon W.R. , Ansell S.M. , Bennani N.N. , Kudva Y.C. , et al. .
Source: Hemasphere, 2021 Oct; 5(10), p. e640.
EPub date: 2021-09-06 00:00:00.0.
PMID: 34514344
Related Citations

Perceptions of clinical care and research among African-American patients with lymphoma.
Authors: Dance K.V. , Imbody C.B. , Chen L. , McNeill L. , Payne J.B. , Flowers C.R. .
Source: Leukemia & Lymphoma, 2021 08; 62(8), p. 1860-1868.
EPub date: 2021-02-28 00:00:00.0.
PMID: 33645400
Related Citations

The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma.
Authors: Abeykoon J.P. , Hampel P.J. , King R.L. , Wood A.J. , Larson M.C. , Nowakowski K.E. , Zanwar S.S. , Dasari S. , Ruan G.J. , Ravindran A. , et al. .
Source: Haematologica, 2021-08-01 00:00:00.0; 106(8), p. 2261-2264.
EPub date: 2021-08-01 00:00:00.0.
PMID: 33657788
Related Citations

Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era.
Authors: Boddicker N.J. , Larson M.C. , Castellino A. , Herrmann J. , Inwards D.J. , Thanarajasingam G. , Maurer M.J. , Allmer C. , Witzig T.E. , Nowakowski G.S. , et al. .
Source: American Journal Of Hematology, 2021-08-01 00:00:00.0; 96(8), p. 979-988.
EPub date: 2021-05-27 00:00:00.0.
PMID: 33971040
Related Citations

Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era.
Authors: Arushi Khurana null , Mwangi R. , Ansell S.M. , Habermann T.M. , Cerhan J.R. , Strouse C. , Link B.K. , Wang Y. , King R.L. , Macon W.R. , et al. .
Source: Blood Cancer Journal, 2021-07-17 00:00:00.0; 11(7), p. 133.
EPub date: 2021-07-17 00:00:00.0.
PMID: 34274939
Related Citations

Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma.
Authors: Mondello P. , Fama A. , Larson M.C. , Feldman A.L. , Villasboas J.C. , Yang Z.Z. , Galkin I. , Svelolkin V. , Postovalova E. , Bagaev A. , et al. .
Source: Blood Cancer Journal, 2021-07-15 00:00:00.0; 11(7), p. 130.
EPub date: 2021-07-15 00:00:00.0.
PMID: 34267181
Related Citations

Surveillance imaging during first remission in follicular lymphoma does not impact overall survival.
Authors: Goldman M.L. , Mao J.J. , Strouse C.S. , Chen W. , Rupji M. , Chen Z. , Maurer M.J. , Calzada O. , Churnetski M. , Flowers C.R. , et al. .
Source: Cancer, 2021-06-22 00:00:00.0; , .
EPub date: 2021-06-22 00:00:00.0.
PMID: 34157780
Related Citations

Body mass index and survival of patients with lymphoma.
Authors: Chihara D. , Larson M.C. , Robinson D.P. , Thompson C.A. , Maurer M.J. , Casulo C. , Pophali P. , Link B.K. , Habermann T.M. , Feldman A.L. , et al. .
Source: Leukemia & Lymphoma, 2021-06-14 00:00:00.0; , p. 1-8.
EPub date: 2021-06-14 00:00:00.0.
PMID: 34121594
Related Citations

Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?
Authors: Khurana A. , Mwangi R. , Nowakowski G.S. , Habermann T.M. , Ansell S.M. , LaPlant B.R. , Link B.K. , Cerhan J.R. , Maurer M.J. , Witzig T.E. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2021-05-20 00:00:00.0; 39(15), p. 1641-1649.
EPub date: 2021-02-02 00:00:00.0.
PMID: 33529046
Related Citations

Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
Authors: Maurer M.J. , Jakobsen L.H. , Mwangi R. , Schmitz N. , Farooq U. , Flowers C.R. , de Nully Brown P. , Thompson C.A. , Frederiksen H. , Cunningham D. , et al. .
Source: American Journal Of Hematology, 2021-05-01 00:00:00.0; 96(5), p. 599-605.
EPub date: 2021-03-18 00:00:00.0.
PMID: 33661547
Related Citations

Epidemiology of Marginal Zone Lymphoma.
Authors: Cerhan J.R. , Habermann T.M. .
Source: Annals Of Lymphoma, 2021 Mar; 5, .
EPub date: 2021-03-30 00:00:00.0.
PMID: 33829216
Related Citations

Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.
Authors: Hartert K.T. , Wenzl K. , Krull J.E. , Manske M. , Sarangi V. , Asmann Y. , Larson M.C. , Maurer M.J. , Slager S. , Macon W.R. , et al. .
Source: Leukemia, 2021 02; 35(2), p. 522-533.
EPub date: 2020-03-05 00:00:00.0.
PMID: 32139889
Related Citations

The association of health behaviors with quality of life in lymphoma survivors.
Authors: Pophali P.A. , Larson M.C. , Rosenthal A.C. , Robinson D. , Habermann T.M. , Thanarajasingam G. , Call T. , Allmer C. , Farooq U. , Maurer M.J. , et al. .
Source: Leukemia & Lymphoma, 2021 02; 62(2), p. 271-280.
EPub date: 2020-10-13 00:00:00.0.
PMID: 33047636
Related Citations

Analysis and impact of a multidisciplinary lymphoma virtual tumor board.
Authors: Habermann T.M. , Khurana A. , Lentz R. , Schmitz J.J. , von Bormann A.G. , Young J.R. , Hunt C.H. , Christofferson S.N. , Nowakowski G.S. , McCullough K.B. , et al. .
Source: Leukemia & Lymphoma, 2020 12; 61(14), p. 3351-3359.
EPub date: 2020-09-23 00:00:00.0.
PMID: 32967496
Related Citations

Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients.
Authors: Krull J.E. , Wenzl K. , Hartert K.T. , Manske M.K. , Sarangi V. , Maurer M.J. , Larson M.C. , Nowakowski G.S. , Ansell S.M. , McPhail E. , et al. .
Source: Blood Cancer Journal, 2020-11-09 00:00:00.0; 10(11), p. 117.
EPub date: 2020-11-09 00:00:00.0.
PMID: 33168821
Related Citations